Physician profile
Rodolfo B Protacio
NPI 1154320836
$11,155.24
in general payments reported to CMS, 2019-2025
33 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $900 · 2021: $2,333 · 2022: $2,992 · 2023: $810 · 2024: $1,885 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,989 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,988.54 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,890.75 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $1,047.36 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $883.72 | 2021-2025 | |
| Mannkind Corporation | $679.19 | 2019-2025 | Afrezza |
| Amgen INC. | $643.85 | 2022-2025 | Evenity, Prolia, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $553.54 | 2019-2025 | Farxiga, Nexium |
| Boehringer Ingelheim Pharmaceuticals, INC. | $521.79 | 2019-2025 | Jardiance |
| Abbvie INC. | $520.06 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $497.14 | 2020-2023 | Verquvo |
| Lilly USA, LLC | $458.81 | 2019-2025 | Zepbound, Amyvid, Mounjaro |
| Glaxosmithkline, LLC. | $431.12 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.65 | 2021-2024 | Xifaxan |
| Ardelyx, INC. | $287.88 | 2024-2025 | Ibsrela |
| Sunovion Pharmaceuticals INC. | $271.55 | 2019-2022 | |
| Amarin Pharma, INC. | $255.90 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $250.74 | 2020-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $242.53 | 2019-2022 | |
| Dexcom, INC. | $224.92 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $191.34 | 2021-2022 | |
| Astellas Pharma US INC | $183.40 | 2019-2021 | |
| Veryan Medical Incorporated | $130.95 | 2022 | |
| Sumitomo Pharma America, INC. | $125.30 | 2024-2025 | Gemtesa |
| Angiodynamics, INC. | $104.76 | 2022 | |
| Shield Therapeutics INC | $81.25 | 2024-2025 | |
| Arbor Pharmaceuticals, INC. | $67.02 | 2021 | |
| Phathom Pharmaceuticals, INC. | $66.28 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $39.44 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $38.07 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $35.18 | 2019-2020 | |
| Hologic Sales and Service, LLC | $24.37 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $21.23 | 2025 | |
| Pfizer INC. | $19.11 | 2019 | |
| Abiomed | $19.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodolfo Protacio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.